7TN1 image
Entry Detail
PDB ID:
7TN1
Keywords:
Title:
Multistate design to stabilize viral class I fusion proteins
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2022-01-20
Release Date:
2023-07-12
Method Details:
Experimental Method:
Resolution:
3.10 Å
R-Value Free:
0.31
R-Value Work:
0.25
R-Value Observed:
0.25
Space Group:
P 41 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Fusion glycoprotein F0
Chain IDs:A (auth: F), B (auth: A), C (auth: B)
Chain Length:568
Number of Molecules:3
Biological Source:Respiratory syncytial virus
Ligand Molecules
Primary Citation
A general computational design strategy for stabilizing viral class I fusion proteins.
Nat Commun 15 1335 1335 (2024)
PMID: 38351001 DOI: 10.1038/s41467-024-45480-z

Abstact

Many pathogenic viruses rely on class I fusion proteins to fuse their viral membrane with the host cell membrane. To drive the fusion process, class I fusion proteins undergo an irreversible conformational change from a metastable prefusion state to an energetically more stable postfusion state. Mounting evidence underscores that antibodies targeting the prefusion conformation are the most potent, making it a compelling vaccine candidate. Here, we establish a computational design protocol that stabilizes the prefusion state while destabilizing the postfusion conformation. With this protocol, we stabilize the fusion proteins of the RSV, hMPV, and SARS-CoV-2 viruses, testing fewer than a handful of designs. The solved structures of these designed proteins from all three viruses evidence the atomic accuracy of our approach. Furthermore, the humoral response of the redesigned RSV F protein compares to that of the recently approved vaccine in a mouse model. While the parallel design of two conformations allows the identification of energetically sub-optimal positions for one conformation, our protocol also reveals diverse molecular strategies for stabilization. Given the clinical significance of viruses using class I fusion proteins, our algorithm can substantially contribute to vaccine development by reducing the time and resources needed to optimize these immunogens.

Legend

Protein

Chemical

Disease

Primary Citation of related structures